Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial

Jan C. Koch, Andreas Leha, Helen Bidner, Isabell Cordts, Johannes Dorst, René Günther, Daniel Zeller, Nathalie Braun, Moritz Metelmann, Philippe Corcia, Elisa De La Cruz, Patrick Weydt, Thomas Meyer, Julian Großkreutz, Marie Hélène Soriani, Shahram Attarian, Jochen H. Weishaupt, Ute Weyen, Josua Kuttler, Gabriela ZurekMary Louise Rogers, Emily Feneberg, Marcus Deschauer, Christoph Neuwirth, Joanne Wuu, Albert C. Ludolph, Jens Schmidt, Yvonne Remane, William Camu, Tim Friede, Michael Benatar, Markus Weber, Paul Lingor, ROCK-ALS Study group, Danielle Renfrey

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)
18 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science